The U.S. Food and Drug Administration approves an immunotherapy for certain adults with untreated rectal cancer, with the goal of allowing some patients to avoid additional treatments. Multiple outlets report that the approval is for a subset of rectal cancer cases, where the therapy is described as effective without the need for surgery, chemotherapy, or radiation in those patients.

TIME and Medical Xpress both focus on the potential treatment change this approval represents. Both frame the decision as enabling a less intensive approach for some patients rather than applying to all cases. The coverage emphasizes the newly approved immunotherapy and its role in reducing or eliminating the usual combination of surgery, chemotherapy, and radiation for eligible people.

While the outlets align on the core message—approval of dostarlimab-gxly for certain untreated rectal cancers—their framing differs slightly, with one emphasizing the broader implication that some patients may “skip” multiple modalities, and the other highlighting the FDA approval details and the drug’s specific name.